Esperion Therapeutics ESPR Disallowed business interest expense carryforward
Disallowed business interest expense carryforward at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetInterestCarryforward.
The official record: Esperion Therapeutics’s 10-K, filed March 10, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's disallowed business interest expense carryforward.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's disallowed business interest expense carryforward?
- Esperion Therapeutics (ESPR) reported disallowed business interest expense carryforward of $39.84M in Q4 2025.
- How has Esperion Therapeutics's disallowed business interest expense carryforward changed year-over-year?
- Esperion Therapeutics's disallowed business interest expense carryforward decreased by 3.8% year-over-year, from $41.43M to $39.84M.
- What is the long-term trend for Esperion Therapeutics's disallowed business interest expense carryforward?
- Over 5 years (2020 to 2025), Esperion Therapeutics's disallowed business interest expense carryforward has grown at a 49.7% compound annual growth rate (CAGR), from $5.31M to $39.84M.